Dr. Corina Antal is a V Scholar Grantee and an Assistant Professor in the Department of Pharmacology at the University of California San Diego and a member of the Moores Cancer Center. Her work focuses on some of the most urgent challenges in cancer research: finding new ways to treat pancreatic cancer, one of the deadliest and most treatment-resistant cancers, as well as triple-negative breast cancer, an aggressive subtype with limited targeted treatment options. Dr. Antal first drew national attention for overturning long-standing scientific assumptions about how certain cancer-related proteins function, work that earned her recognition on Forbes’ “30 Under 30” list in Science. During her postdoctoral training at the Salk Institute, she turned her focus to pancreatic cancer, where she began identifying hidden molecular weaknesses that could be exploited to slow or stop tumor growth. Today, her laboratory studies how disruptions in RNA processing help cancer grow, spread, and resist treatment. By uncovering how these hidden molecular control systems break down, Dr. Antal is working to reveal entirely new therapeutic targets, opening the door to treatments that could expand options and improve outcomes for patients who currently have very few. Recently, Dr. Antal and her team uncovered a previously unrecognized weakness in triple-negative breast cancer; by targeting it in their studies, they were able to shrink tumors.
Mailing List
